ALT 801

Drug Profile

ALT 801

Alternative Names: 264scTCR/IL-2; ALT-801; STAR™-Ck

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Altor BioScience Corporation
  • Developer Altor BioScience Corporation; Florida Department of Health; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer; Multiple myeloma; Urogenital cancer
  • No development reported Acute myeloid leukaemia; Malignant melanoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)
  • 04 Oct 2016 Altor Bioscience and NantKwest agree to co-develop combination immunotherapies for Cancer
  • 13 Jul 2016 Altor Bioscience terminates its phase Ib/II trial for Multiple myeloma (Second-line therapy or greater) in USA as patients did not benefit from single agent treatment(NCT01670994)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top